Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson purchased 101,119 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was purchased at an average price of $7.42 per share, with a total value of $750,302.98. Following the completion of the purchase, the chief executive officer directly owned 635,456 shares of the company’s stock, valued at approximately $4,715,083.52. This represents a 18.92% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Troy Edward Wilson also recently made the following trade(s):
- On Friday, November 13th, Troy Wilson acquired 98,881 shares of Kura Oncology stock. The stock was purchased at an average cost of $7.63 per share, with a total value of $754,462.03.
- On Monday, August 24th, Troy Wilson acquired 100,000 shares of Kura Oncology stock. The shares were purchased at an average price of $12.39 per share, for a total transaction of $1,239,000.00.
Kura Oncology Stock Performance
NASDAQ:KURA traded down $0.68 during trading hours on Monday, reaching $7.09. 2,621,535 shares of the stock were exchanged, compared to its average volume of 2,345,466. The company has a quick ratio of 4.71, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. The firm has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $9.76. Kura Oncology, Inc. has a 52 week low of $6.75 and a 52 week high of $13.90. The stock has a market capitalization of $651.43 million, a P/E ratio of -2.15 and a beta of 0.56.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. The company had revenue of $22.84 million during the quarter, compared to analyst estimates of $24.94 million. As a group, sell-side analysts forecast that Kura Oncology, Inc. will post -3.20 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kura Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. IFP Advisors Inc grew its holdings in shares of Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after purchasing an additional 1,467 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of Kura Oncology by 842.5% during the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after purchasing an additional 2,519 shares during the period. Physician Wealth Advisors Inc. bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $49,000. Finally, Allworth Financial LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $113,000.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Deutsche Bank set a $24.00 price objective on Kura Oncology in a research note on Wednesday, October 14th. Barclays set a $24.00 target price on shares of Kura Oncology in a research note on Wednesday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. JPMorgan Chase & Co. started coverage on shares of Kura Oncology in a report on Thursday, October 1st. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $25.88.
Check Out Our Latest Research Report on Kura Oncology
About Kura Oncology
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Featured Articles
- Five stocks we like better than Kura Oncology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
